StockWatch
·
SEQUENT SCIENTIFIC LTD. · QQ2 FY-2027 · THE CALL

Strong YoY growth, capex cuts signal moderation

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsVIYASHSEQUENT SCIENTIFIC LTD.17 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Met BioForLife timeline. Cut capex guidance without warning. YoY growth narrative (16.2%) conflicts with filed result (133%), raising transparency questions.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Viyash posted ₹988 Cr revenue with solid asset growth and BioForLife integration ahead, anchoring multi-year optionality. However, delivered results show 133% YoY growth but management highlighted only 16.2%—suggesting either quality-of-earnings concern or acquisition accounting. Capex cut from ₹250–300 to ₹140–150 Cr (40% reduction) signals moderation. Near-term caution (10% FY27 growth) conflicts with long-term ₹1B by FY32 (17–18% CAGR) thesis. Hold pending FY27 H2 visibility and capex rationalization.

₹987.9 Cr

Revenue · +133% YoY

₹84.7 Cr

Reported PAT · +331.9% YoY

Compressing

Margins · vs guidance: Contradicted

Did the claims hold up?

Management's claims vs. the numbers

Q2 FY27 revenue ₹988 Cr, up 16.2% YoY

MISS

Delivered Q2 FY27 revenue ₹987.9 Cr, up 133% YoY per filed results

Q2 profit ₹85 Cr, up 16% YoY

MISS

Delivered Q2 PAT ₹84.7 Cr, up 331.9% YoY

Gross margin 53.7% Q2, stable at 54–55% forward

OVERSTATED

Delivered gross margin not separately stated; NPM 8.5%, OPM 16.7%

Capex ₹140–150 Cr this year

MET

Prior guidance was ₹250–300 Cr; new guidance ₹140–150 Cr

Companion animal business at ₹20–30M, ~60% growth

OVERSTATED

Delivery numbers don't segment by companion vs farm animals; claim not independently verified

Earnings quality

What changed since the last call

Deltas vs. the prior call

Capex guidance slashed 40%

Downgrade

FY27 capex cut from ₹250–300 Cr to ₹140–150 Cr. Animal health facility scaled back; strategy shifted to 'optimize capex' over next 2–3 years at ₹150 Cr.

BioForLife acquisition completed Oct 1

New

On schedule per prior guidance. 100% stake acquired; consolidation from Q3 FY27. Opens geo-extension (Europe, emerging markets) and high-potency manufacturing.

API and companion animal growth tracking

Neutral

API guidance reaffirmed 12–13% FY27 (vs prior 13–15%). Companion animal ₹30M (+60% YoY) now primary focus (up from ₹20M base last year).

U.S. business momentum slowdown

Downgrade

Exclusive product (CGT) generated $5M with 90%+ margin Q2 FY26; now ending. U.S. expected ₹480 Cr (15% YoY growth), lower than prior high-teens expectations.

The Q&A

Analysts pressed hard on U.S. business deceleration, capex cuts, gross margin volatility, and YoY growth slowdown. Management held firm on long-term strategy (animal health, 2029 patent expirations, ₹1B by FY32) but was defensive on near-term: attributed U.S. slowdown to one-time exclusive product, margins to war/input costs, and capex cut to 'optimization.' Tone confident but guarded on FY27 outlook (10% growth only).

The exchanges that mattered

U.S. business growth slowdown — Gourav Bhama, JM Financial

Answered

One exclusive product (CGT, $5M, 90% margin) ended after six-month window. Without exclusivity, U.S. base business normalizing; we expect ₹480 Cr (15% growth) for the year.

CDMO/API competition — Kenil Mehta, Boring AMC

Partial

CDMO majority is farm animals (mature, differentiated). API working on strategic tie-ups; not at new chemical entity stage yet. We have 5-year visibility on most blockbuster products.

API growth trajectory & segment split — Anubhav Sangal, Anand Rathi

Answered

API mid-teens (12–13%) FY27; companion animal $20–30M (60% growth); animal health ramped up 3x. We're at ₹30M companion now.

Emerging markets growth breakdown — Vishal Manchanda, Systematix

Answered

Brazil 40% volume growth, Turkey good growth on new launches, Mexico stable. Strongest near-term expansion in Turkey and Brazil.

Gross margin drivers — Aman Goyal, IIFL

Answered

War-driven raw material inflation, solvent/price variance ~0.3–0.4%. Slight product mix change. Confident on 54–55% recovery forward through process efficiency.

Formulation vs API split & capex plan — Bharat Sheth, Quest

Answered

Formulation will grow to 65–75% over 2–3 years via new products & acquisitions. Capex now ₹140–150 Cr this year (down from earlier ₹250–300 Cr); expect stable ₹150 Cr going forward.

U.S. generic market size & strategy — Chintan Modi, Oaklane

Partial

Europe 50–60% generics now, expect 70–80% by 2029–2030. U.S. 15–20% generic opportunity; we target 15–20% market share in niche high-potency molecules.

Patent expirations & oncology R&D — Vishal Manchanda, Systematix

Answered

2029 is major patent expiration year (₹3B+ market, 10 filings in advanced stage). Oncology center built; para IV products starting validation; expect material contribution FY30.

Carlyle stake & 20% growth feasibility — Kushal Goenka, Mangal Keshav

Partial

Carlyle exploring exit next 12–15 months. We're confident on 20%+ growth. Infrastructure, R&D, strong balance sheet (net debt ₹26 Cr), and ₹1B FY32 target at 17–18% CAGR are achievable. Organic + inorganic.

Guidance

Forward guidance and management's confidence

FY27 overall 10% growth (confidence level)

Medium

Post-H1 momentum of 17.8% ease assumed. Near-term caution due to U.S. exclusivity wind-down and API demand headwinds (geopolitical).

API 12–13% FY27 (vs prior 13–15%)

Medium

Slight cut from earlier range. Mid-teens is mid-term target pending patent expirations 2029+.

Companion animal ₹30M (~60% growth) FY27

High

Already achieved ₹20–30M in H1; confidence high on 2029+ launches and geographic expansion.

Gross margin 54–55% FY27 forward

Medium

Q2 at 53.7%; expect recovery via process efficiency, pricing actions, and product mix (animal health higher margin).

EBITDA margin ~21% (healthy from ESOP normalization)

High

H1 EBITDA margin 21.3% ex-ESOP. ESOP normalized Q1 FY28; expect stable 20–22% margin band forward.

FY27 capex ₹140–150 Cr (down from ₹250–300 Cr prior)

High

Animal health facility (₹60 Cr spent; ₹60–80 Cr remaining). Optimization push; next 2–3 years ~₹150 Cr annualized.

FY28+ capex ₹140–150 Cr annualized, optimized

Medium

Post-BioForLife integration and companion animal facility, capex expected to stabilize at lower run rate.

Risks the call surfaced

Ranked by how much they should concern a holder

API market demand

High

War-driven customer procurement delays and inventory normalization impacting API visibility. Q1 demand weak; Q2 recovery partial.

Gross margin sustainability

Medium

Q2 gross margin 53.7% vs 55.5% prior year. War-driven raw material inflation and solvent price volatility cited. Recovery to 54–55% assumed but not guaranteed.

U.S. business slowdown

Medium

U.S. exclusive product (CGT, $5M, 90% margin) ended H1. Base U.S. business expected ₹480 Cr (15% growth) vs high-teens prior. Generics at 15–20%, expected to reach 70–80% by 2029–2030 in Europe.

Capex cut implications

Medium

Capex cut from ₹250–300 Cr to ₹140–150 Cr (40% reduction). Companion animal facility commissioning Q1 FY28; delay risk. Animal health R&D expansion may slow.

Patent expiration timing risk

Medium

Major patent expirations 2029 open ₹3B+ market. 20+ filings in advanced stages. Delays in regulatory approvals (FDA, EMA) could push revenue contribution to 2030 or later.

Quality of earnings

High

Management highlighted 16.2% YoY revenue growth in call. Delivered result shows 133% YoY. Likely acquisition accounting or prior-year restatement not disclosed. Raises transparency concerns.

Management

Score 7/10. Detailed and strategic on long-term roadmap (animal health, patent expirations, new product launches). Transparent on headwinds (war impact, margin pressure, U.S. slowdown). However, communication gap: highlighted 16.2% growth while filed result is 133%, raising clarity concerns. Complex explanations sometimes obscure the main narrative. Met BioForLife acquisition timeline (Oct 1). Animal health R&D tripled and showing 60% companion animal growth. Companion animal facility on track Q1 FY28. However, capex cut from ₹250–300 to ₹140–150 Cr (40%) without prior warning signals moderation or execution risk on growth plans.

What to watch next
  • 1 · Q1 FY28

    Companion animal facility commissioning; BioForLife full consolidation

  • 2 · 2028–2029

    First wave of major new product launches (20+ filings in advanced stages)

  • 3 · 2029 onwards

    Patent expirations open $3B+ market opportunity; generic entry possible

Hold pending FY27 H2 visibility and capex rationalization.

Informational and educational content only. Not investment advice.